CLDN3 and ovarian cancer: Furthermore, other target treatments for CLDN3, siRNA therapy or recombinant shRNA plasmid and cisplatin, have been shown to inhibit ovarian cancer progression and reduce the amount of cytotoxic drugs [41–44].